Equine MEED genomics study points to a new mutation target

A new genomics report in Animals adds early molecular clues to equine multisystemic eosinophilic epitheliotropic disease, or MEED, a rare, often fatal inflammatory disorder with no clearly defined genetic basis. According to the study abstract, investigators performed roughly 40× whole-genome sequencing on an affected horse and compared the genome with 40 controls, identifying more than 6.3 million variants and finding enrichment of moderate- and high-impact variants among rare and private changes. Additional conference material from the same Texas Tech University group points to a heterozygous stop-gained variant in USP25 as their top candidate signal, with structural modeling used to prioritize possible disease-relevant mutations. (depts.ttu.edu)

Why it matters: For equine veterinarians, the work is less about an immediately practice-ready test and more about moving MEED out of the purely descriptive case-report era. MEED is rare, difficult to diagnose ante-mortem, and typically presents with nonspecific signs involving the skin, gastrointestinal tract, liver, lungs, and other organs. Current references still describe its pathogenesis as poorly understood, though some sources have long suggested a possible genetic predisposition in horses. A plausible candidate gene tied to immune signaling could eventually support better case stratification, future diagnostic development, and more targeted research into pathogenesis. (academic.oup.com)

What to watch: Watch for the full peer-reviewed paper and any follow-up validation in additional MEED cases to determine whether USP25 is a reproducible disease signal or a single-case finding. (depts.ttu.edu)